Showing 26–50 of 185 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Festjens N, Vandewalle K, Houthuys E, Plets E, Vanderschaeghe D, et al.
The Mycobacterium bovis Bacille Calmette Guérin (BCG) vaccine shows variable efficacy in protection against adult tuberculosis (TB). Earlier, we have described a BCG mutant vaccine with a transposon insertion in the gene coding for the secreted acid phosphatase SapM, which led to…
Yun Xu, Xiaochun Wang, Qiangsen Zhong
Bacillus Calmette-Guérin (BCG) is the only vaccine currently used in clinical practice to prevent tuberculosis (TB), however, it remains limited in preventing latent infection, TB reactivation, and providing comprehensive protection. In this study, the pcaA gene, an antigen …
Ari MM, Beig M, Sholeh M, Khoshmirsafa M
…usative agent for this infection. Different antibiotics and vaccines have been discussed as potential treatments and prevention. Currently, there is only one licensed vaccine against TB, Bacillus Calmette-Guérin (BCG). Despite its protective efficacy against TB in children, BCG h…
Socorro Miranda-Hernandez, Harindra D Sathkumara, Guangzu Zhao, Louis Schofield, Andreas Kupz
…er 1 million lives annually. Bacillus Calmette-Guérin (BCG), the only licensed vaccine against TB, provides limited efficacy against pulmonary TB in adults and only partial protection against serious disease in children. Hence, the development of safer and more effective new…
Dockrell HM, Butkeviciute E
The BCG vaccine will, in 2021, have been in use for 100 years. Much remains to be understood, including the reasons for its variable efficacy against pulmonary tuberculosis in adults. This review will discuss what has been learnt about the BCG vaccine in the last two decades, and…
Lidia Del Pozo-Ramos, Andreas Kupz
…ausing over a million deaths annually. The only licensed TB vaccine for human use, Bacille Calmette-Guérin (BCG), a mycobacteria-based live-attenuated vaccine, confers immunity to children but fails to efficiently protect adults from pulmonary TB. Several TB vaccine candidat…
Prabowo SA, Smith SG, Seifert K, Fletcher HA
Understanding factors associated with varying efficacy of Bacillus Calmette-Guérin (BCG) would aid the development of improved vaccines against tuberculosis (TB). In addition, investigation of individual-level factors affecting mycobacterial-specific immune responses could provid…
Clark RA, Weerasuriya CK, Portnoy A, Mukandavire C, Quaife M, et al.
…n tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/AS01 E and BCG-revaccination have recently completed phase IIb trials and estimates of their population-level impact are needed. We estimated the…
Walk J, de Bree LCJ, Graumans W, Stoter R, van Gemert GJ, et al.
Recent evidence suggests that certain vaccines, including Bacillus-Calmette Guérin (BCG), can induce changes in the innate immune system with non-specific memory characteristics, termed 'trained immunity'. Here we present the results of a randomised, controlled phase 1 clinical t…
Lei Q, Fu H, Yao Z, Zhou Z, Wang Y, et al.
Background The Bacillus Calmette-Guérin (BCG) vaccine, currently the sole authorized vaccine against tuberculosis (TB), demonstrates limited effectiveness in safeguarding adolescents and adults from active TB, even when administered as a booster with either BCG itself or heterolo…
Chen Z, Zhang Y, Wu J, Xu J, Hu Z, et al.
…remains a global challenge. Despite being the only licensed vaccine, Bacillus Calmette-Guérin (BCG) confers limited protective efficacy in adults and individuals with latent tuberculosis infections (LTBI). There is an urgent need to develop novel vaccines that can enhance the pro…
Wang H, Wang S, Fang R, Li X, Xing J, et al.
…ion, predominantly reliant on the Bacillus Calmette-Guérin (BCG) vaccine. Although it is effective in preventing disseminated diseases in children, its impact on adults is limited. To broaden vaccine protection, efforts are underway to accelerate the development of new TB vaccine…
Satti I, Marshall JL, Harris SA, Wittenberg R, Tanner R, et al.
…m tuberculosis is the main causative agent of tuberculosis. BCG, the only licensed vaccine, provides inadequate protection against pulmonary tuberculosis. Controlled human infection models are useful tools for vaccine development. We aimed to determine a safe dose of aerosol-inha…
Fatima S, Kumari A, Das G, Dwivedi VP
…spite years of intensive research, Bacille Calmette-Guerin (BCG) remains the only licensed vaccine and has variable efficacy. It provides protection against childhood TB but is not effective in adult pulmonary TB. As a result of intense research in understanding TB vaccinology, t…
Xiaochun Wang, Qiangsen Zhong, Yun Xu, Xinkuang Liu
Bacillus Calmette-Guérin (BCG) vaccine has limited protection against tuberculosis (TB) in adults, and there is an urgent need to develop novel TB vaccines. Currently, booster vaccines based on initial immunization with BCG are important research hotspots. In this study, we …
Nieuwenhuizen NE, Zyla J, Zedler U, Bandermann S, Abu Abed U, et al.
BCG - the only available vaccine against tuberculosis (TB) - was first given to babies 100 years ago in 1921. While it is effective against TB meningitis and disseminated TB, its efficacy against pulmonary TB is variable, notably in adults and adolescents. TB remains one of the w…
Fritschi N, Curtis N, Ritz N
The Bacille Calmette Guérin (BCG) vaccine was developed over a century ago and has become one of the most used vaccines without undergoing a modern vaccine development life cycle. Despite this, the vaccine has protected many millions from severe and disseminated forms of tubercul…
Negi K, Bhaskar A, Dwivedi VP
…t to improve the TB control program comprising one approved vaccine, M. bovis Bacille Calmette-Guerin (BCG) has directed researchers to explore progressive approaches to halt the eternal TB pandemic. Mycobacterium tuberculosis ( M.tb ) was first identified as the causative agent …
van den Berg RA, De Mot L, Leroux-Roels G, Bechtold V, Clement F, et al.
…s the potential to identify gene signatures associated with vaccine immunogenicity and protective efficacy. The main objective of this study was to identify optimal postvaccination time points for evaluating peripheral blood RNA expression profiles in relation to vaccine immunoge…
Wu Y, Cai M, Ma J, Teng X, Tian M, et al.
Adults are the leading population affected by tuberculosis (TB) epidemic and death. Developing an effective vaccine against adult TB is urgently needed. Mycobacterium bovis Bacillus Calmette-Guerin (BCG) prime-heterologous boost strategy has been explored extensively to protect a…
Nilofer Naqvi, Anwar Alam, Mohd Shariq, Yashika Ahuja, Dipendra K Mitra, et al.
…a global health burden, particularly because of the limited efficacy of the Bacillus Calmette-Guérin (BCG) vaccine against adult pulmonary TB. To improve immunogenicity, we developed a recombinant BCG strain expressing the M. tuberculosis -specific antigen Rv1507A (rBCG_Rv15…
Marcellus Korompis, Christopher J De Voss, Shuailin Li, Alberta Ateere, Helen McShane, et al.
…and mortality worldwide, and Bacillus Calmette-Guérin (BCG) offers inconsistent protection against adult pulmonary TB. We previously showed that homologous mRNA vaccination encoding the mycobacterial antigen PPE15 (mRNA.PPE15) enhanced immunogenicity but did not improve prot…
Yun JS, Shin E, Lee YR, Lee JA, Lee H, et al.
Introduction The inadequate efficacy of the Bacillus Calmette-Guérin (BCG) vaccine against adult pulmonary tuberculosis (TB) necessitates the development of new and effective vaccines. Human adenovirus serotype 5 (Ad5), which induces T-cell response, is a widely used viral vector…
Adesanya OA, Uche-Orji CI, Adedeji YA, Joshua JI, Adesola AA, et al.
Background The Bacillus Calmette-Guerin (BCG) vaccine has been in use for 99 years, and is regarded as one of the oldest human vaccines known today. It is recommended primarily due to its effect in preventing the most severe forms of tuberculosis, including disseminated tuberculo…
Ramos L, Lunney JK, Gonzalez-Juarrero M
Neonatal and infant immunity differs from that of adults in both the innate and adaptive arms, which are critical contributors to immune-mediated clearance of infection and memory responses elicited during vaccination. The tuberculosis (TB) research community has openly admitted …